New malaria vaccine schedule trial aims to protect infants

NCT ID NCT06879327

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: PATH Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests the R21/Matrix-M malaria vaccine in about 964 African infants to find the best timing for shots. Researchers compare a compressed schedule (6, 10, 14 weeks) with relaxed schedules (2, 4, 6 months or 3, 6, 9 months) to see which works best with other routine vaccines. The goal is to improve protection against malaria in young children.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALARIA VACCINES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Plasmodium falciparum malaria malaria prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Groupe de Recherche Action en Santé (GRAS)

    RECRUITING

    Ouagadougou, Burkina Faso

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Institut de Recherche en Sciences de la Santé (IRSS)

    RECRUITING

    Bobo-Dioulasso, Burkina Faso

    Contact Phone: •••-•••-•••• Email: •••••@•••••